PUBLISHER: The Business Research Company | PRODUCT CODE: 2057522
PUBLISHER: The Business Research Company | PRODUCT CODE: 2057522
The BNP and NT-proBNP market consists of revenues generated by entities (organizations, sole traders and partnerships) through the development, manufacture and provision of immunoassay-based test kits, reagents, calibrators, controls and analyzer systems used to quantitatively measure BNP and NT-proBNP levels in blood samples. These tests are primarily used by cardiologists, emergency physicians, internists and general practitioners in hospitals, emergency departments, outpatient clinics and specialized cardiac centers to evaluate patients presenting with symptoms such as dyspnea, edema and fatigue. They are used in acute settings for rapid triage and in chronic care settings for disease monitoring and risk stratification.
The global BNP and NTproBNP market was valued at $1,245.5 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 12.00%.
Rising Awareness Of Early Diagnosis And Preventive Cardiology
During the historic period, the BNP and NT-proBNP market was significantly driven by the rising awareness of early diagnosis and preventive cardiology. Early diagnosis and preventive cardiology refer to the proactive identification and management of cardiovascular risk and early-stage heart conditions using clinical screening, biomarkers and risk assessment tools before severe disease develops. It is increasing primarily due to the growing global burden of heart failure and cardiac risk populations, which is driving routine screening and earlier clinical intervention. BNP and NT-proBNP testing supports early diagnosis and preventive cardiology by enabling rapid biomarker-based detection of cardiac stress and dysfunction, allowing clinicians to stratify risk and initiate timely preventive treatment. For instance, in October 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, In 2021-22, Australia recorded about 148,000 hospitalizations with coronary heart disease as the main diagnosis, representing 1.3% of all hospital admissions and 26% of cardiovascular disease-related hospitalizations. In 2022, coronary heart disease was also the underlying cause of roughly 18,600 deaths, accounting for about 9.8% of all deaths nationwide. Therefore, the BNP and NT-proBNP market was significantly driven by the rising awareness of early diagnosis and preventive cardiology in the historic period.
Biotechnology, Genomics And Precision Medicine
Companies in the BNP and NT-proBNP market are increasingly prioritizing biotechnology, genomics and precision medicine to enhance diagnostic accuracy and early cardiovascular risk detection, supporting the development of more sensitive biomarker assays and personalized testing strategies, enabling improved patient stratification and more targeted clinical decision-making and strengthening precision-based and data-driven cardiac care solutions. Biotechnology, genomics and precision medicine support BNP and NT-proBNP testing by enabling highly sensitive biomarker assays and advanced molecular diagnostic platforms that improve early and accurate detection of heart failure and related cardiac conditions. For instance, in April 2024, Roche Diagnostics India Pvt Ltd, an India-based pharmaceutical company, launched an NT-proBNP test for diabetes patients at risk of CVD to support early identification of cardiovascular complications and enable timely clinical intervention, with the test designed for routine screening and faster risk evaluation in high-risk diabetic populations, reshaping preventive cardiology screening and integrated biomarker-based disease management.
The global BNP and NTproBNP market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 34.5% of the total market in 2024.
BNP And NT-proBNP Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global BNP and NT-proBNP market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market forBNP and NT-proBNP? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The BNP and NT-proBNP market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the BNP and NT-proBNP; and compares it with other markets.